Pancreatic Cancer Clinical Trials
One of the unique benefits of being a University of Michigan patient is access to the latest and most promising therapies for cancer. Our doctors are working hard to find cures, but they can't do it alone. Patients play a vital role by participating in research studies -- also known as clinical trials.
The links to information about clinical trials will open in a second browser window. Close this window to return to this page for further browsing..
2013.095 Phase 2 Study of Gemcitabine, Cisplatin +/- Veliparib in Patients With Pancreas Adenocarcinoma with BRCA/ PALB2 Mutation and a Phase 2 Study of Veliparib in Previously Treated Pancreas Adenocarcinoma
2015.130 An Open-Label, Multicenter, Single-Arm, Phase 1/2 Study of Metronomic 5-Fluorouracil in Combination with Nabpaclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients with Metastatic Pancreatic Adenocarcinoma (FABLOx)
UMCC 2016.081 A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitbine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinom
ECOG-ACRIN EA2142 Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
ECOG-ACRIN EA2142 / HUM00109831 Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
2008.092 Radiation Oncology Bioresource Study
HUM00025339 Assessment of Biological Markers in Pancreatic (for information, please call 800-865-1125)
Role of Wearable Wireless Accelerometers in Pancreatic Cancer (for information, please call 800-865-1125)
If you would like to speak to someone about these trials available at the University of Michigan, please contact the Cancer AnswerLine™ at 800-865-1125.